article information

Anesthesiology and Pain Medicine: Vol.13, issue 1; e127017
published online: February 6, 2023
article type: Research Article
received: December 5, 2022
revised: January 1, 2023
accepted: January 8, 2023
DOI: https://doi.org/10.5812/aapm-127017
Crossmark

Comparison of Perioperative Pregabalin and Duloxetine for Pain Management After Total Knee Arthroplasty: A Double-Blind Clinical Trial

authors:

avatar Farnad Imani ORCID 1 , avatar Azadeh Emami ORCID 1 , avatar Mahzad Alimian ORCID 1 , avatar Nasim Nikoubakht ORCID 1 , avatar Niloofar Khosravi ORCID 1 , * , avatar Mehdi Rajabi ORCID 2 , ** , avatar Arthur Christopher Hertling ORCID 3

Pain Research Center, Department of Anesthesiology and Pain Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Department of Anesthesiology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
Department of Anesthesiology, Perioperative Care and Pain Medicine, School of Medicine, New York University, New York, USA
Corresponding Authors:

how to cite: Imani F, Emami A, Alimian M, Nikoubakht N, Khosravi N, et al. Comparison of Perioperative Pregabalin and Duloxetine for Pain Management After Total Knee Arthroplasty: A Double-Blind Clinical Trial. Anesth Pain Med. 2023;13(1):e127017. https://doi.org/10.5812/aapm-127017.

Abstract

Background:

Chronic residual pain after total knee arthroplasty (TKA) is one of the challenges of postoperative pain management. Duloxetine, by controlling neuropathic pain, and pregabalin, by affecting nociceptors, can effectively manage postoperative pain.

Objectives:

This study aimed to compare the effect of perioperative oral duloxetine and pregabalin in pain management after knee arthroplasty.

Methods:

In this clinical trial, 60 patients scheduled for TKA under spinal anesthesia were randomly assigned to one of three groups A (pregabalin 75 mg), B (duloxetine 30 mg), and C (placebo). Drugs were administered 90 minutes before, 12, and 24 hours after surgery. The visual analog scale (VAS) score for pain, the first analgesic request time, postoperative analgesic consumption (i.v. paracetamol), and WOMAC score six months after surgery were recorded.

Results:

The VAS score and analgesic consumption 48 hours after TKA in groups A and B significantly decreased compared to the placebo (P < 0.05). The first analgesic request time was longer in groups A and B than in group C (P < 0.05). While the differences were statistically significant, they are most likely not clinically significant. The WOMAC score before and six months after arthroplasty did not differ between the groups (P > 0.05).

Conclusions:

Perioperative oral pregabalin and duloxetine similarly reduce pain and the need for analgesic consumption within 48 hours after TKA but do not affect knee mobility status.

1. Background

Knee osteoarthritis is a prevalent joint disorder, and various medical, non-medical, and surgical methods have been offered for its treatment (1-4). Total knee arthroplasty (TKA) is one of the most common orthopedic surgeries, which reduces pain, improves function, and enhances the quality of life of patients with knee osteoarthritis. However, about 20% to 35% of patients undergoing this surgery are still dissatisfied, mainly due to chronic residual pain (5). Inadequate management of postoperative pain leads to prolonged hospitalization, increased cost of care, delayed rehabilitation, and increased risk of postoperative complications (6). Therefore, various pharmacological and non-pharmacological methods have been used to control acute and chronic pain and perioperative pain (7-10).

So far, there have been studies on the effects of gabapentinoids, duloxetine, dexmedetomidine, ketamine, lidocaine, magnesium, and regional blocks (11-17). Despite the advances in pain management, opioids are still commonly used to treat these conditions (18). Duloxetine is a norepinephrine and serotonin reuptake inhibitor widely prescribed for major depressive disorders, generalized anxiety disorders, diabetic peripheral neuropathy, and chronic musculoskeletal pain (12). Duloxetine increases norepinephrine and serotonin and ultimately improves the descending inhibitory effects in the central nervous system. The analgesic effects of duloxetine are independent of its antidepressant effects, and it has similar analgesic effects in both groups of depressed and non-depressed patients. In some studies, the analgesic effects of duloxetine in chronic musculoskeletal pain have been observed, but its impact on perioperative TKA pain control is debatable (19).

Pregabalin is a structural analog of GABA and is an anticonvulsant drug that selectively affects the process of pain transmission through nociceptors by inhibiting calcium channels. Compared to gabapentin, pregabalin has better oral absorption and bioavailability. Recently, pregabalin has been considered an adjuvant drug in the management of neuropathic and postoperative pain, and several studies have shown that it reduces acute pain and postoperative opioid consumption following some surgeries (20). Its perioperative administration may help prevent chronic postoperative pain. Studies report conflicting results about pregabalin's effects, which is a matter of controversy (21). There are studies on the effectiveness of duloxetine and pregabalin in controlling pain after TKA, but no comparative study has been conducted to determine which of these two drugs is more effective in controlling postoperative pain.

2. Objectives

This clinical trial aimed to compare the effect of perioperative administration of pregabalin and duloxetine on pain management after total knee arthroplasty.

3. Methods

After the approval of the Ethics Committee of the Iran University of Medical Sciences (code: IR.IUMS.FMD.REC.1398.378) and the Iranian Registry of Clinical Trials (IRCT code: IRCT20190719044276N1), in this randomized, double-blind placebo control clinical trial, TKA candidate patients were studied according to the CONSORT guidelines (Figure 1). Eligibility criteria included age 40 to 75 years and ASA I-II candidates for TKA under spinal anesthesia. Patients with lower extremity neuropathic pain, drug abuse, psychological disorders, drug sensitivity, severe cardiac, renal, or hepatic diseases, or refusing regional anesthesia were excluded. Allocating patients to the studied groups was done by a blinded collaborator not involved in study procedures. Patients and clinical researchers were also blinded to the groups and interventions.

Clinical trial flowchart (CONSORT flowchart)
Clinical trial flowchart (CONSORT flowchart)
Figure 1.

Clinical trial flowchart (CONSORT flowchart)

Our primary outcome was the VAS score at 48 hours. Secondary outcomes were analgesic use at 48 hours, time to first analgesic request, and the WOMAC scores six months after surgery compared to the preoperative score.

The sample size of 60 patients (i.e., 20 patients per group) was determined based on the sample size calculation formula. The maximum sample size was calculated by considering the confidence level of 95% and a power of 90% using the following formula (including 15% attrition):

Patients were divided into three equal groups (n=20) according to the block randomization method. Group A received pregabalin 75 mg, group B duloxetine 30 mg, and group C placebo. Intervention (prescription of drugs) was performed in all groups three times, 90 minutes before surgery, then 12 and 24 hours after surgery. After obtaining written informed consent, all patients were subjected to standard monitoring, including pulse oximetry, ECG, and non-invasive blood pressure. Ringer's solution (500 mL) was infused. In the sitting position, a 25G Quincke spinal needle was inserted into the intrathecal space through the L4 - 5 intervertebral space. After the free flow of CSF, bupivacaine 0.5% (AstraZeneca, Austria) 10 mg and fentanyl 25 μg were slowly injected. After obtaining the appropriate level of anesthesia, the surgery would begin. If spinal anesthesia was unsuccessful, general anesthesia would be performed, and the subject would be excluded. During the first postoperative day, if the VAS score was more than 3 in every four visits, i.v. paracetamol 1 g (Apotel, Uni-pharma Co., Greece) was administered. The VAS scores were recorded 6, 12, 24, and 48 hours after surgery, and the WOMAC scores before and six months after surgery. The dose of paracetamol consumed 6, 12, 24, and 48 hours after the surgery and the first analgesic request time were also investigated.

3.1. Data Analysis

Patient data were analyzed using SPSS version 22 statistical software. Central indices (mean and SD) were used to report quantitative parameters. Frequency (%) was used to report qualitative parameters. The normality of the distribution of the parameters was determined using the Kolmogorov-Smirnov test. Considering the independence of the study groups, with the assumption of normal distribution of the variables, ANOVA was used to compare more than two groups. The Kruskal-Wallis non-parametric test was used to compare variables in three groups. The chi-square test was used to analyze qualitative variables in groups. A repeated measurement test was used to compare the index at different times during the treatment. A P value < 0.05 was considered statistically significant.

4. Results

In this clinical trial, 67 patients were screened for inclusion. Five patients were excluded because they did not meet the inclusion criteria, and two were excluded because they did not consent to participate in the study. Finally, 60 patients were studied in three equal groups (n = 20). During the intervention and follow-up, no patient had to be excluded from the study (Figure 1).

Demographics and results are shown in Table 1. No significant difference was observed in demographic variables among the three groups at the beginning of the study. The mean VAS score at all times in the three groups and the time to first analgesic request were statistically significantly different between groups A and B, on the one hand, and group C on the other, but there was no significant difference between groups A and B. No significant difference was observed in the WOMAC score between the three groups.

Table 1.

Demographic Data, VAS Score, WOMAC Score, and Paracetamol Consumption

VariablesABCP Value
Age (y)66.8 ± 7.067.6 ± 4.365.5 ± 6.40.18
Sex; No. (%)0.15
Male3 (15)1 (5)0 (0)
Female17 (85)19 (95)20 (100)
Surgery duration (h)2.1 ± 0.52.2 ± 0.42.1 ± 0.30.62
VAS (h)
65.0 ± 1.04.8 ± 0.95.2 ± .080.001
123.2 ± 0.93.5 ± 0.84.9 ± 1.00.001
242.7 ± 1.12.4 ± 1.03.8 ± 0.90.017
482.1 ± 0.91.9 ± 0.82.7 ± 1.00.01
First analgesic request time (h)16.9 ± 1.717.1 ± 2.215.4 ± 1.60.001
Paracetamol (g)
6 h0.7 ± 0.40.9 ± 0.51.0 ± 0.50.033
12 h0.6 ± 0.50.8 ± 0.40.9 ± 0.60.001
24 h0.5 ± 0.10.6 ± 0.31.2 ± 0.60.03
48 h0.6 ± 0.20.6 ± 0.11.6 ± 0.50.001
WOMAC
Before63.2 ± 5.163.5 ± 3.262.8 ± 4.20.89
6 months26.6 ± 3.925.9 ± 3.926.3 ± 3.20.82

The mean consumption of i. v. paracetamol in the first six hours was significantly lower in group A than in groups B and C (P = 0.03). In contrast, no significant difference was reported between groups B and C (P = 0.11). In the first 12 hours, it was lower in group A than in groups B and C (P = 0.033), but no significant difference was observed between groups B and C (P = 0.11). Twenty-four hours after surgery, it was higher in group C than in groups A and B (P = 0.03). But there was no significant difference between groups A and B (P = 0.19). Forty-eight hours after surgery, it was significantly higher in group C than in groups A and B (P = 0.001), while no significant difference was reported between groups A and B (P = 0.58). The trend of paracetamol consumption over time in the three groups was statistically different (P = 0.001). No complications were observed with administering these two drugs in the patients.

5. Discussion

In this study, oral perioperative pregabalin and duloxetine in knee arthroplasty significantly reduced postoperative pain score and analgesic consumption. However, a reduction in VAS by less than 20 mm or paracetamol dose by less than 1 g was probably not clinically significant but did not affect knee movement status (WOMAC score) six months after surgery.

Since pain after TKA can have both nociceptive and neuropathic origins, using effective drugs to treat neuropathic and nociceptive pain can control knee arthroplasty pain (22, 23). Duloxetine can play the role of desensitizing the CNS in patients with central sensitization and thus be effective in controlling neuropathic pain after TKA (24). On the other hand, pregabalin can selectively affect the process of pain transmission through nociceptors and be efficient in managing pain after arthroplasty (25). There are many studies on the effectiveness of these two drugs in controlling pain after TKA, but no study has been conducted to compare these two drugs in controlling pain after TKA (21, 24).

There are several studies with different doses of perioperative pregabalin for pain management after knee arthroplasty, but there are few studies with a dose of 75 mg. A high perioperative dose of pregabalin leads to optimal pain management after TKA and improves knee range of motion after surgery. In the study of Buvanendran et al., pregabalin 300 mg was prescribed before TKA and pregabalin 150 mg for 14 days after surgery (26). Patients were screened for neuropathic pain three and six months after surgery. Secondary outcomes included postoperative recovery and rehabilitation measures, including knee range of motion, opioid use, postoperative pain scores, sleep disturbance, discharge time, and postoperative complications. Their study showed that postoperative pregabalin was associated with less analgesic consumption and improved range of motion during the first four weeks of rehabilitation. It also reduced the incidence of chronic neuropathic pain. However, it was associated with a higher risk of early postoperative sedation and confusion at tested doses. Similar to our study, Jain et al. investigated the effect of pregabalin 75 mg compared with a placebo on pain management after TKA (27). This drug was prescribed before the operation and continued twice a day for 48 hours after arthroplasty. Their study showed that pregabalin significantly reduced mean pain score and analgesic consumption during the first 48 hours after surgery. The results of our study are also consistent with their research, as significant reductions in pain, paracetamol consumption, and time to the first analgesic request were observed in the first 48 hours after the surgery.

In addition to pain and analgesic consumption, knee movement status (WOMAC score) was also examined in our study. However, some studies have contradicted these results. In the YaDeau et al.’s study, pregabalin (0, 50, 100, or 150 mg) was administered from before to two weeks after surgery (28). They stated that pregabalin did not have beneficial analgesic effects, and their results did not support the preoperative administration of pregabalin for TKA patients. In general, due to contradictory results in prescribing pregabalin in TKA pain management, it is recommended to conduct more studies with various doses.

The use of duloxetine in controlling TKA pain is based on the logic that part of the pain after TKA may have a neuropathic origin that occurs due to central sensitivity. Therefore, pain can be controlled by desensitizing the CNS with drugs such as duloxetine. Evaluating the effect of duloxetine on the amount of morphine needed after knee arthroplasty, Ho et al. showed that the administration of duloxetine after surgery could reduce the need for morphine in the first 48 hours after surgery, but it did not affect pain and side effects (24). YaDeau et al. administered duloxetine 60 mg daily for 14 days to evaluate its impact on subacute pain after TKA. Their study showed no reduction in pain at rest or during knee flexion, but opioid use and nausea were significantly reduced (29).

Patients with central sensitization have more severe pain after TKA, and, as a result of taking more opioids, so the analgesic effect of perioperative duloxetine in knee arthroplasty can be significantly stronger in these patients. Koh et al. investigated the effects of duloxetine on pain scores after TKA in patients with previous central sensitization. In their study, duloxetine reduced postoperative pain and improved the quality of postoperative recovery without increasing side effects (30). Based on previous studies, for patients with central sensitization before TKA, perioperative duloxetine to the multimodal analgesia protocol may reduce postoperative pain and opioid consumption and improve the quality of recovery without increasing the risk of complications (24, 30). Therefore, oral duloxetine is effective when central sensitization exists before the surgery, i.e., when the origin of knee osteoarthritis pain is neuropathic, while it may be ineffective in other patients. Therefore, the results of our study regarding the successful postoperative pain management after TKA following duloxetine may indicate that most of our patients in the duloxetine group had central sensitization before the surgery. However, there are currently insufficient clinical data to recommend the routine use of duloxetine in patients with central sensitization to improve pain after TKA.

As the results were statistically significant for both medications, but the improvement was too small to be clinically significant, the next step might be to set up a study using a combination of pregabalin and duloxetine to see whether the combined effect would be clinically significant.

5.1. Conclusion

Perioperative oral pregabalin and duloxetine similarly reduced pain and the need for analgesic within 48 hours after TKA in a statistically significant but not clinically significant fashion but did not affect knee mobility after six months. The effects of these two drugs on the amount of pain, time, and analgesic consumption, as well as the knee's movement status, were similar. According to the mechanism of action of duloxetine, it is more logical to prescribe it to patients with neuropathic pain, where it can play a role in desensitizing the central nervous system. Conversely, it is more reasonable to prescribe pregabalin for cases other than central sensitization. As most patients seem to have both neuropathic and nociceptive pain, a multimodal regimen combining both medications might be more effective than each alone, but this hypothesis remains to be investigated.

References

  • 1.

    Imani F, Patel VB. Therapeutic Challenges for Knee Osteoarthritis. Anesth Pain Med. 2019;9(3). e95377. [PubMed ID: 31497526]. [PubMed Central ID: PMC6712428]. https://doi.org/10.5812/aapm.95377.

  • 2.

    Rahimzadeh P, Imani F, Faiz SHR, Entezary SR, Zamanabadi MN, Alebouyeh MR. The effects of injecting intra-articular platelet-rich plasma or prolotherapy on pain score and function in knee osteoarthritis. Clin Interv Aging. 2018;13:73-9. [PubMed ID: 29379278]. [PubMed Central ID: PMC5757490]. https://doi.org/10.2147/cia.s147757.

  • 3.

    Imani F, Hejazian K, Kazemi MR, Narimani-Zamanabadi M, Malik KM. Adding Ozone to Dextrose and Somatropin for Intra-articular Knee Prolotherapy: A Randomized Single-Blinded Controlled Trial. Anesth Pain Med. 2020;10(5). e110277. [PubMed ID: 34150571]. [PubMed Central ID: PMC8207853]. https://doi.org/10.5812/aapm.110277.

  • 4.

    Rezasoltani Z, Dadarkhah A, Tabatabaee SM, Abdorrazaghi F, Kazempour Mofrad M, Kazempour Mofrad R. Therapeutic Effects of Intra-articular Botulinum Neurotoxin Versus Physical Therapy in Knee Osteoarthritis. Anesth Pain Med. 2021;11(3). e112789. [PubMed ID: 34540630]. [PubMed Central ID: PMC8438713]. https://doi.org/10.5812/aapm.112789.

  • 5.

    Rhon DI, Greenlee TA, Carreño PK, Patzkowski JC, Highland KB. Pain Catastrophizing Predicts Opioid and Health-Care Utilization After Orthopaedic Surgery: A Secondary Analysis of Trial Participants with Spine and Lower-Extremity Disorders. J Bone Joint Surg Am. 2022;104(16):1447-54. [PubMed ID: 35700089]. https://doi.org/10.2106/jbjs.22.00177.

  • 6.

    Lindberg MF, Miaskowski C, Rustøen T, Cooper BA, Aamodt A, Lerdal A. Preoperative risk factors associated with chronic pain profiles following total knee arthroplasty. Eur J Pain. 2021;25(3):680-92. [PubMed ID: 33259681]. [PubMed Central ID: PMC7986219]. https://doi.org/10.1002/ejp.1703.

  • 7.

    Soleimanpour H, Imani F, Dolati S, Soleimanpour M, Shahsavarinia K. Management of pain using magnesium sulphate: a narrative review. Postgrad Med. 2022;134(3):260-6. [PubMed ID: 35086408]. https://doi.org/10.1080/00325481.2022.2035092.

  • 8.

    Imani F, Bagheri AR, Arvin E, Gatt SP, Sarveazad A. Effects of Ketamine and Lidocaine Infusion on Acute Pain after Elective Open Abdominal Surgery, a Randomized, Double-Blinded Study. Med J Islam Repub Iran. 2022;36:60. [PubMed ID: 36128312]. [PubMed Central ID: PMC9448502]. https://doi.org/10.47176/mjiri.36.60.

  • 9.

    Edinoff AN, Girma B, Trettin KA, Horton CC, Kaye AJ, Cornett EM, et al. Novel Regional Nerve Blocks in Clinical Practice: Evolving Techniques for Pain Management. Anesth Pain Med. 2021;11(4). e118278. [PubMed ID: 34692446]. [PubMed Central ID: PMC8520672]. https://doi.org/10.5812/aapm.118278.

  • 10.

    Imani F, Entezary S, Razi M, Jafarian AA, Yousefshahi F, Etemadi H, et al. The effect of intra-articular meperidine and bupivacaine 0.5% on postoperative pain of arthroscopic knee surgery; a randomized double blind clinical trial. Anesth Pain Med. 2015;5(1). e27470. [PubMed ID: 25830119]. [PubMed Central ID: PMC4363738]. https://doi.org/10.5812/aapm.27470.

  • 11.

    Pinto Filho WA, Silveira LHJ, Vale ML, Fernandes CR, Alves Gomes J. The Effect of Gabapentin on Postoperative Pain of Orthopedic Surgery of Lower Limb by Sciatic and Femoral Blockage in Children: A Clinical Trial. Anesth Pain Med. 2019;9(4). e91207. [PubMed ID: 31754608]. [PubMed Central ID: PMC6825328]. https://doi.org/10.5812/aapm.91207.

  • 12.

    Bastanhagh E, Zamiri F, Samimi Sadeh S, Adabi K, Pourfakhr P. Effect of Preoperative Duloxetine on Opioid Consumption in Women Undergoing Abdominal Hysterectomy: A Randomized, Double-Blinded, Placebo-Controlled Trial. Anesth Pain Med. 2020;10(5). e103729. [PubMed ID: 34150561]. [PubMed Central ID: PMC8207876]. https://doi.org/10.5812/aapm.103729.

  • 13.

    Imani F, Varrassi G. Ketamine as Adjuvant for Acute Pain Management. Anesth Pain Med. 2019;9(6). e100178. [PubMed ID: 32280623]. [PubMed Central ID: PMC7119219]. https://doi.org/10.5812/aapm.100178.

  • 14.

    Imani F, Zaman B, De Negri P. Postoperative Pain Management: Role of Dexmedetomidine as an Adjuvant. Anesth Pain Med. 2020;10(6). e112176. [PubMed ID: 34150582]. [PubMed Central ID: PMC8207883]. https://doi.org/10.5812/aapm.112176.

  • 15.

    Tully J, Jung JW, Patel A, Tukan A, Kandula S, Doan A, et al. Utilization of Intravenous Lidocaine Infusion for the Treatment of Refractory Chronic Pain. Anesth Pain Med. 2020;10(6). e112290. [PubMed ID: 34150583]. [PubMed Central ID: PMC8207879]. https://doi.org/10.5812/aapm.112290.

  • 16.

    Urits I, Jung JW, Amgalan A, Fortier L, Anya A, Wesp B, et al. Utilization of Magnesium for the Treatment of Chronic Pain. Anesth Pain Med. 2021;11(1). e112348. [PubMed ID: 34221945]. [PubMed Central ID: PMC8236839]. https://doi.org/10.5812/aapm.112348.

  • 17.

    Rhatomy S, Rahmadian R, Alam Rasyid F, Margaretha E. Adductor Canal Block in the Outpatient Clinic for Pain Control Following Knee Surgery. Anesth Pain Med. 2021;11(1). e110904. [PubMed ID: 34221939]. [PubMed Central ID: PMC8239381]. https://doi.org/10.5812/aapm.110904.

  • 18.

    Malik KM, Imani F, Beckerly R, Chovatiya R. Risk of Opioid Use Disorder from Exposure to Opioids in the Perioperative Period: A Systematic Review. Anesth Pain Med. 2020;10(1). e101339. [PubMed ID: 32337175]. [PubMed Central ID: PMC7158240]. https://doi.org/10.5812/aapm.101339.

  • 19.

    de Oliveira Filho GR, Kammer RS, Dos Santos HC. Duloxetine for the treatment acute postoperative pain in adult patients: A systematic review with meta-analysis. J Clin Anesth. 2020;63:109785. [PubMed ID: 32179396]. https://doi.org/10.1016/j.jclinane.2020.109785.

  • 20.

    Mishriky BM, Waldron NH, Habib AS. Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. Br J Anaesth. 2015;114(1):10-31. [PubMed ID: 25209095]. https://doi.org/10.1093/bja/aeu293.

  • 21.

    Canihuante J, Molina I, Altermatt F. Is perioperative pregabalin effective for reducing postoperative pain in major surgery? Medwave. 2017;17(9). e7115. [PubMed ID: 29286353]. https://doi.org/10.5867/medwave.2017.09.7115.

  • 22.

    Kurien T, Arendt-Nielsen L, Petersen KK, Graven-Nielsen T, Scammell BE. Preoperative Neuropathic Pain-like Symptoms and Central Pain Mechanisms in Knee Osteoarthritis Predicts Poor Outcome 6 Months After Total Knee Replacement Surgery. J Pain. 2018;19(11):1329-41. [PubMed ID: 29920331]. https://doi.org/10.1016/j.jpain.2018.05.011.

  • 23.

    Malfait AM, Schnitzer TJ. Towards a mechanism-based approach to pain management in osteoarthritis. Nat Rev Rheumatol. 2013;9(11):654-64. [PubMed ID: 24045707]. [PubMed Central ID: PMC4151882]. https://doi.org/10.1038/nrrheum.2013.138.

  • 24.

    Ho KY, Tay W, Yeo MC, Liu H, Yeo SJ, Chia SL, et al. Duloxetine reduces morphine requirements after knee replacement surgery. Br J Anaesth. 2010;105(3):371-6. [PubMed ID: 20573635]. https://doi.org/10.1093/bja/aeq158.

  • 25.

    Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73(2):137-50. [PubMed ID: 17126531]. https://doi.org/10.1016/j.eplepsyres.2006.09.008.

  • 26.

    Buvanendran A, Kroin JS, Della Valle CJ, Kari M, Moric M, Tuman KJ. Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial. Anesth Analg. 2010;110(1):199-207. [PubMed ID: 19910619]. https://doi.org/10.1213/ANE.0b013e3181c4273a.

  • 27.

    Jain P, Jolly A, Bholla V, Adatia S, Sood J. Evaluation of efficacy of oral pregabalin in reducing postoperative pain in patients undergoing total knee arthroplasty. Indian J Orthop. 2012;46(6):646-52. [PubMed ID: 23325966]. [PubMed Central ID: PMC3543881]. https://doi.org/10.4103/0019-5413.104196.

  • 28.

    YaDeau JT, Lin Y, Mayman DJ, Goytizolo EA, Alexiades MM, Padgett DE, et al. Pregabalin and pain after total knee arthroplasty: a double-blind, randomized, placebo-controlled, multidose trial. Br J Anaesth. 2015;115(2):285-93. [PubMed ID: 26170351]. [PubMed Central ID: PMC4500762]. https://doi.org/10.1093/bja/aev217.

  • 29.

    YaDeau JT, Brummett CM, Mayman DJ, Lin Y, Goytizolo EA, Padgett DE, et al. Duloxetine and Subacute Pain after Knee Arthroplasty when Added to a Multimodal Analgesic Regimen: A Randomized, Placebo-controlled, Triple-blinded Trial. Anesthesiology. 2016;125(3):561-72. [PubMed ID: 27387351]. https://doi.org/10.1097/aln.0000000000001228.

  • 30.

    Koh IJ, Kim MS, Sohn S, Song KY, Choi NY, In Y. Duloxetine Reduces Pain and Improves Quality of Recovery Following Total Knee Arthroplasty in Centrally Sensitized Patients: A Prospective, Randomized Controlled Study. J Bone Joint Surg Am. 2019;101(1):64-73. [PubMed ID: 30601417]. https://doi.org/10.2106/jbjs.18.00347.